$5370 | Single User
$7800 | Enterprise License

Pneumonia Testing Market by Method (Immunodiagnostics, Molecular Diagnostics, and Point of Care Testing), Technology (Enzyme Linked Immunosorbent Assay, Immunofluorescence, Western Blot, Polymerase Chain Reaction, Immunohistochemistry, and Others), Type (Analyzers and Consumables), and End User (Hospitals, Diagnostic Laboratories, Homecare, and Others) - Global Opportunity Analysis and Industry Fo
[Lowest Price Guaranteed: $5,370]

Published by Allied Market Research: 01 Nov 2017 | 152931 | In Stock
Related Topics: Abbott , Bioscience , Home , Molecular Diagnostics , Pneumonia , Polymerase Chain Reaction (PCR) , Roche , Technology

Introduction

Pneumonia is indicated as a complex infection, which affects the lower part of the respiratory tract along with deposition of cough in the lungs. It may even occur as a consequence to an upper tract infection. Frequently, it occurs in people with weakened immunity, and in geriatric population and children. Biotechnological methods can be approached for testing of pneumonia such as enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction (PCR). The global pneumonia testing market was valued at 2 million in 2016, and is estimated to reach ,738 million by 2023, registering a CAGR of 9.2% from 2017 to 2023.

The report segments the pneumonia testing market by method, type, technology, end user, and region. In terms of method, the market is classified into immunodiagnostics, molecular diagnostics, and point-of-care (POC) testing. Based on technology, it is categorized into enzyme-linked immunosorbent assay (ELISA), immunofluorescence, western blot, polymerase chain reaction (PCR), immunohistochemistry (IHC), and others. By type, it is bifurcated into analyzers and consumables. Depending on end user, it is divided into hospitals, diagnostic laboratories, homecare, and others. Based on region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Increased awareness regarding early diagnosis, rise in popularity of POC testing, and surge in government expenditures on healthcare. However, limited detection capability and accuracy of some of the pneumonia testing products and regulatory and economic hurdles hamper the market growth. Some of the factors such as increase in adoption of molecular diagnostic testing and untapped markets in developing economies could open avenues of opportunities for the pneumonia testing market.

KEY MARKET BENEFITS

This report offers a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities.

The market estimations provided in this report are based on comprehensive analysis of the key developments in the industry.

In-depth analysis based on geography facilitates in analyzing the regional market to assist in strategic business planning.

The development strategies adopted by key manufacturers are enlisted in the report to understand the competitive scenario of the market.

KEY PLAYERS PROFILED

Thermo Fisher Scientific Inc.

Abbott Laboratories

F-Hoffmann la Roche Ltd.

Hologic Inc.

bioMerieux

Becton, Dickenson and Company

Bio-Rad Laboratories Inc.

Meridian Biosciences

Quest Diagnostics

Quidel

Pneumonia Testing Market key SEGMENTS:

By Method

Immunodiagnostics

Molecular Diagnostics

Point of Care (POC) Testing

By Technology

Enzyme-linked Immunosorbent Assay (ELISA)

Immunofluorescence

Western Blot

Polymerase Chain Reaction (PCR)

Immunohistochemistry (IHC)

Others

By Type

Analyzers

Consumables

By End User

Hospitals

Diagnostic Laboratories

Homecare

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

UK

France

Spain

Italy

Rest of Europe

Asia-Pacific

Japan

China

Australia

India

South Korea

Taiwan

Rest of Asia-Pacific

LAMEA

Brazil

South Africa

Saudi Arabia

Rest of LAMEA

The other players of the pneumonia testing market include (companies not profiled in the report):

AdvanDx

Beckman Coulter

Cepheid

Concile

Diamedix

DiaSorin

Fast-track Diagnostics

SeraCare

Trinity Biotech.

Table of Contents
for Pneumonia Testing Market by Method (Immunodiagnostics, Molecular Diagnostics, and Point of Care Testing), Technology (Enzyme Linked Immunosorbent Assay, Immunofluorescence, Western Blot, Polymerase Chain Reaction, Immunohistochemistry, and Others), Type (Analyzers and Consumables), and End User (Hospitals, Diagnostic Laboratories, Homecare, and Others) - Global Opportunity Analysis and Industry Fo

  • CHAPTER 1 INTRODUCTION

    1.1. KEY BENEFITS

    1.2. KEY MARKET SEGMENTS

    1.3. RESEARCH METHODOLOGY

    1.3.1. Secondary research

    1.3.2. Primary research

    1.3.3. Analyst tools and models

    CHAPTER 2 EXECUTIVE SUMMARY

    2.1. CXO PERSPECTIVE

    CHAPTER 3 MARKET OVERVIEW

    3.1. MARKET DEFINITION AND SCOPE

    3.2. KEY FINDINGS

    3.2.1. Top investment pockets, 2016

    3.2.2. Top winning strategies

    3.3. TOP PLAYER POSITIONING, 2016

    3.4. PORTERS FIVE FORCES ANALYSIS

    3.5. MARKET DYNAMICS

    3.5.1. Drivers

    3.5.1.1. Surge in awareness towards early diagnosis

    3.5.1.2. Rise in popularity of POC testing

    3.5.1.3. Increase in government expenditure on healthcare

    3.5.2. Restraints

    3.5.2.1. Limited detection capability and accuracy

    3.5.2.2. Regulatory and economic hurdles

    3.5.3. Opportunities

    3.5.3.1. Increase in adoption of molecular diagnostic testing

    3.5.3.2. Untapped markets in the developing economies

    CHAPTER 4 PNEUMONIA TESTING MARKET, BY METHOD

    4.1. OVERVIEW

    4.1.1. Market size and forecast

    4.2. IMMUNODIAGNOSTICS

    4.2.1. Key market trends

    4.2.2. Growth factors and opportunities

    4.2.3. Market size and forecast

    4.3. MOLECULAR DIAGNOSTICS

    4.3.1. Key market trends

    4.3.2. Growth factors and opportunities

    4.3.3. Market size and forecast

    4.4. POINT-OF-CARE (POC) TESTING

    4.4.1. Key market trends

    4.4.2. Growth factors and opportunities

    4.4.3. Market size and forecast

    CHAPTER 5 PNEUMONIA TESTING MARKET, BY TECHNOLOGY

    5.1. OVERVIEW

    5.1.1. Market size and forecast

    5.2. ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)

    5.2.1. Market size and forecast

    5.3. IMMUNOFLUORESCENCE

    5.3.1. Market size and forecast

    5.4. WESTERN BLOT

    5.4.1. Market size and forecast

    5.5. POLYMERASE CHAIN REACTION (PCR)

    5.5.1. Market size and forecast

    5.6. IMMUNOHISTOCHEMISTRY (IHC)

    5.6.1. Market size and forecast

    5.7. OTHERS

    5.7.1. Market size and forecast

    CHAPTER 6 PNEUMONIA TESTING MARKET, BY TYPE

    6.1. OVERVIEW

    6.1.1. Market size and forecast

    6.2. ANALYZERS

    6.2.1. Market size and forecast

    6.3. CONSUMABLES

    6.3.1. Market size and forecast

    CHAPTER 7 PNEUMONIA TESTING MARKET, BY END USER

    7.1. OVERVIEW

    7.1.1. Market size and forecast

    7.2. HOSPITALS

    7.2.1. Market size and forecast

    7.3. DIAGNOSTIC CENTERS

    7.3.1. Market size and forecast

    7.4. HOMECARE

    7.4.1. Market size and forecast

    7.5. OTHERS

    7.5.1. Market size and forecast

    CHAPTER 8 PNEUMONIA TESTING MARKET, BY GEOGRAPHY

    8.1. OVERVIEW

    8.1.1. Market size and forecast

    8.2. NORTH AMERICA

    8.2.1. Key market trends

    8.2.2. Key growth factors and opportunities

    8.2.3. Market size and forecast, by method

    8.2.4. Market size and forecast, by technology

    8.2.5. Market size and forecast, by type

    8.2.6. Market size and forecast, by end user

    8.2.7. Market size and forecast, by country

    8.2.7.1. U.S. market size and forecast, by method

    8.2.7.2. U.S. market size and forecast, by technology

    8.2.7.3. U.S. market size and forecast, by type

    8.2.7.4. U.S. market size and forecast, by end user

    8.2.7.5. Canada market size and forecast, by method

    8.2.7.6. Canada market size and forecast, by technology

    8.2.7.7. Canada market size and forecast, by type

    8.2.7.8. Canada market size and forecast, by end user

    8.2.7.9. Mexico market size and forecast, by method

    8.2.7.10. Mexico market size and forecast, by technology

    8.2.7.11. Mexico market size and forecast, by type

    8.2.7.12. Mexico market size and forecast, by end user

    8.3. EUROPE

    8.3.1. Key market trends

    8.3.2. Key growth factors and opportunities

    8.3.3. Market size and forecast, by method

    8.3.4. Market size and forecast, by technology

    8.3.5. Market size and forecast, by type

    8.3.6. Market size and forecast, by end user

    8.3.7. Market size and forecast, by country

    8.3.7.1. Germany market size and forecast, by method

    8.3.7.2. Germany market size and forecast, by technology

    8.3.7.3. Germany market size and forecast, by type

    8.3.7.4. Germany market size and forecast, by end user

    8.3.7.5. France market size and forecast, by method

    8.3.7.6. France market size and forecast, by technology

    8.3.7.7. France market size and forecast, by type

    8.3.7.8. France market size and forecast, by end user

    8.3.7.9. UK market size and forecast, by method

    8.3.7.10. UK market size and forecast, by technology

    8.3.7.11. UK market size and forecast, by type

    8.3.7.12. UK market size and forecast, by end user

    8.3.7.13. Italy market size and forecast, by method

    8.3.7.14. Italy market size and forecast, by technology

    8.3.7.15. Italy market size and forecast, by type

    8.3.7.16. Italy market size and forecast, by end user

    8.3.7.17. Spain market size and forecast, by method

    8.3.7.18. Spain market size and forecast, by technology

    8.3.7.19. Spain market size and forecast, by type

    8.3.7.20. Spain market size and forecast, by end user

    8.3.7.21. Rest of Europe market size and forecast, by method

    8.3.7.22. Rest of Europe market size and forecast, by technology

    8.3.7.23. Rest of Europe market size and forecast, by type

    8.3.7.24. Rest of Europe market size and forecast, by end user

    8.4. ASIA-PACIFIC

    8.4.1. Key market trends

    8.4.2. Key growth factors and opportunities

    8.4.3. Market size and forecast, by method

    8.4.4. Market size and forecast, by technology

    8.4.5. Market size and forecast, by type

    8.4.6. Market size and forecast, by end user

    8.4.7. Market size and forecast, by country

    8.4.7.1. Japan market size and forecast, by method

    8.4.7.2. Japan market size and forecast, by technology

    8.4.7.3. Japan market size and forecast, by type

    8.4.7.4. Japan market size and forecast, by end user

    8.4.7.5. China market size and forecast, by method

    8.4.7.6. China market size and forecast, by technology

    8.4.7.7. China market size and forecast, by type

    8.4.7.8. China market size and forecast, by end user

    8.4.7.9. Australia market size and forecast, by method

    8.4.7.10. Australia market size and forecast, by technology

    8.4.7.11. Australia market size and forecast, by type

    8.4.7.12. Australia market size and forecast, by end user

    8.4.7.13. India market size and forecast, by method

    8.4.7.14. India market size and forecast, by technology

    8.4.7.15. India market size and forecast, by type

    8.4.7.16. India market size and forecast, by end user

    8.4.7.17. South Korea market size and forecast, by method

    8.4.7.18. South Korea market size and forecast, by technology

    8.4.7.19. South Korea market size and forecast, by type

    8.4.7.20. South Korea market size and forecast, by end user

    8.4.7.21. Taiwan market size and forecast, by method

    8.4.7.22. Taiwan market size and forecast, by technology

    8.4.7.23. Taiwan market size and forecast, by type

    8.4.7.24. Taiwan market size and forecast, by end user

    8.4.7.25. Rest of Asia-Pacific market size and forecast, by method

    8.4.7.26. Rest of Asia-Pacific market size and forecast, by technology

    8.4.7.27. Rest of Asia-Pacific market size and forecast, by type

    8.4.7.28. Rest of Asia-Pacific market size and forecast, by end user

    8.5. LAMEA

    8.5.1. Key market trends

    8.5.2. Key growth factors and opportunities

    8.5.3. Market size and forecast, by method

    8.5.4. Market size and forecast, by technology

    8.5.5. Market size and forecast, by type

    8.5.6. Market size and forecast, by end user

    8.5.7. Market size and forecast, by country

    8.5.7.1. Brazil market size and forecast, by method

    8.5.7.2. Brazil market size and forecast, by technology

    8.5.7.3. Brazil market size and forecast, by type

    8.5.7.4. Brazil market size and forecast, by end user

    8.5.7.5. Saudi Arabia market size and forecast, by method

    8.5.7.6. Saudi Arabia market size and forecast, by technology

    8.5.7.7. Saudi Arabia market size and forecast, by type

    8.5.7.8. Saudi Arabia market size and forecast, by end user

    8.5.7.9. South Africa market size and forecast, by method

    8.5.7.10. South Africa market size and forecast, by technology

    8.5.7.11. South Africa market size and forecast, by type

    8.5.7.12. South Africa market size and forecast, by end user

    8.5.7.13. Rest of LAMEA market size and forecast, by method

    8.5.7.14. Rest of LAMEA market size and forecast, by technology

    8.5.7.15. Rest of LAMEA market size and forecast, by type

    8.5.7.16. Rest of LAMEA market size and forecast, by end user

    CHAPTER 9 COMPANY PROFILES

    9.1. ABBOTT LABORATORIES

    9.1.1. Company overview

    9.1.2. Company snapshot

    9.1.3. Operating business segments

    9.1.4. Business performance

    9.1.5. Key strategic moves and developments

    9.2. BECTON, DICKINSON AND COMPANY

    9.2.1. Company overview

    9.2.2. Company snapshot

    9.2.3. Operating business segment

    9.2.4. Business performance

    9.2.5. Key strategic moves and developments

    9.3. BIOMERIEUX S.A.

    9.3.1. Company overview

    9.3.2. Company snapshot

    9.3.3. Operating product solutions

    9.3.4. Business performance

    9.3.5. Key strategic moves and developments

    9.4. BIO-RAD LABORATORIES, INC.

    9.4.1. Company overview

    9.4.2. Company snapshot

    9.4.3. Operating business segments

    9.4.4. Business performance

    9.5. F. HOFFMANN-LA ROCHE AG

    9.5.1. Company overview

    9.5.2. Company snapshot

    9.5.3. Operating business segments

    9.5.4. Business performance

    9.5.5. Key strategic moves and developments

    9.6. HOLOGIC, INC.

    9.6.1. Company overview

    9.6.2. Company snapshot

    9.6.3. Operating business segments

    9.6.4. Business performance

    9.6.5. Key strategic moves and developments

    9.7. MERIDIAN BIOSCIENCE, INC.

    9.7.1. Company overview

    9.7.2. Company snapshot

    9.7.3. Operating business segments

    9.7.4. Business performance

    9.7.5. Key strategic moves and developments

    9.8. QUEST DIAGNOSTICS INCORPORATED

    9.8.1. Company overview

    9.8.2. Company snapshot

    9.8.3. Operating business segments

    9.8.4. Business performance

    9.9. QUIDEL CORPORATION

    9.9.1. Company overview

    9.9.2. Company snapshot

    9.9.3. Business performance

    9.9.4. Key strategic moves and developments

    9.10. THERMO FISHER SCIENTIFIC INC.

    9.10.1. Company overview

    9.10.2. Company snapshot

    9.10.3. Operating business segments

    9.10.4. Business performance

List Of Tables
in Pneumonia Testing Market by Method (Immunodiagnostics, Molecular Diagnostics, and Point of Care Testing), Technology (Enzyme Linked Immunosorbent Assay, Immunofluorescence, Western Blot, Polymerase Chain Reaction, Immunohistochemistry, and Others), Type (Analyzers and Consumables), and End User (Hospitals, Diagnostic Laboratories, Homecare, and Others) - Global Opportunity Analysis and Industry Fo

TABLE 1. GLOBAL PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)

TABLE 2. METHODS AND SAMPLES USED IN IMMUNODIAGNOSTIC METHODS FOR PNEUMONIA TESTING

TABLE 3. IMMUNODIAGNOSTICS PNEUMONIA TESTING MARKET, BY, GEOGRAPHY 2016-2023 ($MILLION)

TABLE 4. MOLECULAR DIAGNOSTICS PNEUMONIA TESTING MARKET, BY GEOGRAPHY 2016-2023 ($MILLION)

TABLE 5. POINT-OF-CARE PNEUMONIA TESTING MARKET, BY, GEOGRAPHY 2016-2023 ($MILLION)

TABLE 6. GLOBAL PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)

TABLE 7. COMMONLY USED ELISA PRODUCTS AND THEIR COMPANY NAMES

TABLE 8. PNEUMONIA TESTING MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAY, BY GEOGRAPHY 2016-2023 ($MILLION)

TABLE 9. PNEUMONIA TESTING MARKET FOR IMMUNOFLUORESCENCE, BY GEOGRAPHY 2016-2023 ($MILLION)

TABLE 10. PNEUMONIA TESTING MARKET FOR WESTERN BLOT, BY GEOGRAPHY 2016-2023 ($MILLION)

TABLE 11. PNEUMONIA TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY GEOGRAPHY 2016-2023 ($MILLION)

TABLE 12. PNEUMONIA TESTING MARKET FOR IMMUNOHISTOCHEMISTRY, BY GEOGRAPHY 2016-2023 ($MILLION)

TABLE 13. COMMONLY USED OTHER TECHNOLOGY PRODUCTS AND THEIR COMPANY NAMES

TABLE 14. PNEUMONIA TESTING MARKET FOR OTHERS TECHNOLOGIES, BY GEOGRAPHY 2016-2023 ($MILLION)

TABLE 15. GLOBAL PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)

TABLE 16. PNEUMONIA TESTING MARKET FOR ANALYZERS, BY GEOGRAPHY, 2016-2023 ($MILLION)

TABLE 17. PNEUMONIA TESTING MARKET FOR CONSUMABLES, BY GEOGRAPHY, 2016-2023 ($MILLION)

TABLE 18. GLOBAL PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)

TABLE 19. PNEUMONIA TESTING MARKET FOR HOSPITALS, BY GEOGRAPHY 2016-2023 ($MILLION)

TABLE 20. PNEUMONIA TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY GEOGRAPHY 2016-2023 ($MILLION)

TABLE 21. PNEUMONIA TESTING MARKET FOR HOMECARE, BY GEOGRAPHY 2016-2023 ($MILLION)

TABLE 22. PNEUMONIA TESTING MARKET FOR OTHERS, BY GEOGRAPHY 2016-2023 ($MILLION)

TABLE 23. PNEUMONIA TESTING MARKET, BY GEOGRAPHY 2016-2023 ($MILLION)

TABLE 24. NORTH AMERICA PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)

TABLE 25. NORTH AMERICA PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)

TABLE 26. NORTH AMERICA PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)

TABLE 27. NORTH AMERICA PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)

TABLE 28. NORTH AMERICA PNEUMONIA TESTING MARKET, BY COUNTRY, 2016-2023 ($MILLION)

TABLE 29. U.S. PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)

TABLE 30. U.S. PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)

TABLE 31. U.S. PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)

TABLE 32. U.S. PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)

TABLE 33. CANADA PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)

TABLE 34. CANADA PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)

TABLE 35. CANADA PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)

TABLE 36. CANADA PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)

TABLE 37. MEXICO PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)

TABLE 38. MEXICO PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)

TABLE 39. MEXICO PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)

TABLE 40. MEXICO PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)

TABLE 41. EUROPE PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)

TABLE 42. EUROPE PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)

TABLE 43. EUROPE PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)

TABLE 44. EUROPE PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)

TABLE 45. EUROPE PNEUMONIA TESTING MARKET, BY COUNTRY, 2016-2023 ($MILLION)

TABLE 46. GERMANY PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)

TABLE 47. GERMANY PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)

TABLE 48. GERMANY PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)

TABLE 49. GERMANY PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)

TABLE 50. FRANCE PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)

TABLE 51. FRANCE PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)

TABLE 52. FRANCE PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)

TABLE 53. FRANCE PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)

TABLE 54. UK PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)

TABLE 55. UK PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)

TABLE 56. UK PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)

TABLE 57. UK PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)

TABLE 58. ITALY PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)

TABLE 59. ITALY PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)

TABLE 60. ITALY PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)

TABLE 61. ITALY PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)

TABLE 62. SPAIN PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)

TABLE 63. SPAIN PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)

TABLE 64. SPAIN PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)

TABLE 65. SPAIN PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)

TABLE 66. REST OF EUROPE PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)

TABLE 67. REST OF EUROPE PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)

TABLE 68. REST OF EUROPE PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)

TABLE 69. REST OF EUROPE PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)

TABLE 70. ASIA-PACIFIC PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)

TABLE 71. ASIA-PACIFIC PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)

TABLE 72. ASIA-PACIFIC PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)

TABLE 73. ASIA-PACIFIC PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)

TABLE 74. ASIA-PACIFIC PNEUMONIA TESTING MARKET, BY COUNTRY, 2016-2023 ($MILLION)

TABLE 75. JAPAN PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)

TABLE 76. JAPAN PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)

TABLE 77. JAPAN PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)

TABLE 78. JAPAN PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)

TABLE 79. CHINA PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)

TABLE 80. CHINA PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)

TABLE 81. CHINA PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)

TABLE 82. CHINA PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)

TABLE 83. AUSTRALIA PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)

TABLE 84. AUSTRALIA PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)

TABLE 85. AUSTRALIA PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)

TABLE 86. AUSTRALIA PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)

TABLE 87. INDIA PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)

TABLE 88. INDIA PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)

TABLE 89. INDIA PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)

TABLE 90. INDIA PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)

TABLE 91. SOUTH KOREA PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)

TABLE 92. SOUTH KOREA PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)

TABLE 93. SOUTH KOREA PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)

TABLE 94. SOUTH KOREA PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)

TABLE 95. TAIWAN PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)

TABLE 96. TAIWAN PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)

TABLE 97. TAIWAN PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)

TABLE 98. TAIWAN PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)

TABLE 99. REST OF ASIA-PACIFIC PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)

TABLE 100. REST OF ASIA-PACIFIC PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)

TABLE 101. REST OF ASIA-PACIFIC PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)

TABLE 102. REST OF ASIA-PACIFIC PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)

TABLE 103. LAMEA PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)

TABLE 104. LAMEA PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)

TABLE 105. LAMEA PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)

TABLE 106. LAMEA PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)

TABLE 107. LAMEA PNEUMONIA TESTING MARKET, BY COUNTRY, 2016-2023 ($MILLION)

TABLE 108. BRAZIL PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)

TABLE 109. BRAZIL PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)

TABLE 110. BRAZIL PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)

TABLE 111. BRAZIL PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)

TABLE 112. SAUDI ARABIA PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)

TABLE 113. SAUDI ARABIA PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)

TABLE 114. SAUDI ARABIA PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)

TABLE 115. SAUDI ARABIA PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)

TABLE 116. SOUTH AFRICA PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)

TABLE 117. SOUTH AFRICA PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)

TABLE 118. SOUTH AFRICA PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)

TABLE 119. SOUTH AFRICA PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)

TABLE 120. REST OF LAMEA PNEUMONIA TESTING MARKET, BY METHOD, 2016-2023 ($MILLION)

TABLE 121. REST OF LAMEA PNEUMONIA TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)

TABLE 122. REST OF LAMEA PNEUMONIA TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)

TABLE 123. REST OF LAMEA PNEUMONIA TESTING MARKET, BY END USER, 2016-2023 ($MILLION)

TABLE 124. ABBOTT: COMPANY SNAPSHOT

TABLE 125. ABBOTT: OPERATING SEGMENTS

TABLE 126. BD: COMPANY SNAPSHOT

TABLE 127. BD: OPERATING SEGMENTS

TABLE 128. BIOMERIEUX S.A.: COMPANY SNAPSHOT

TABLE 129. BIOMRIEUX: PRODUCT SOLUTIONS

TABLE 130. BIO-RAD: COMPANY SNAPSHOT

TABLE 131. BIO-RAD: OPERATING SEGMENTS

TABLE 132. ROCHE: COMPANY SNAPSHOT

TABLE 133. ROCHE: OPERATING SEGMENT

TABLE 134. HOLOGIC: COMPANY SNAPSHOT

TABLE 135. HOLOGIC: OPERATING SEGMENTS

TABLE 136. MERIDIAN: COMPANY SNAPSHOT

TABLE 137. MERIDIAN: OPERATING SEGMENTS

TABLE 138. QUEST DIAGNOSTICS: COMPANY SNAPSHOT

TABLE 139. QUEST DIAGNOSTICS: OPERATING SEGMENTS

TABLE 140. QUIDEL CORPORATION: COMPANY SNAPSHOT

TABLE 141. THERMO FISHER: COMPANY SNAPSHOT

TABLE 142. THERMO FISHER: OPERATING SEGMENTS

List Of Figures, Charts and Diagrams
in Pneumonia Testing Market by Method (Immunodiagnostics, Molecular Diagnostics, and Point of Care Testing), Technology (Enzyme Linked Immunosorbent Assay, Immunofluorescence, Western Blot, Polymerase Chain Reaction, Immunohistochemistry, and Others), Type (Analyzers and Consumables), and End User (Hospitals, Diagnostic Laboratories, Homecare, and Others) - Global Opportunity Analysis and Industry Fo

FIGURE 1. GLOBAL PNEUMONIA TESTING MARKET SEGMENTATION

FIGURE 2. TOP INVESTMENT POCKETS, BY TECHNOLOGY, 2016

FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2016)

FIGURE 4. TOP WINNING STRATEGIES: NATURE AND TYPE

FIGURE 5. TOP PLAYER POSITIONING, 2016

FIGURE 6. LOW BARGAINING POWER OF BUYERS

FIGURE 7. MODERATE BARGAINING POWER OF SUPPLIERS

FIGURE 8. LOW THREAT OF NEW ENTRANTS

FIGURE 9. LOW THREAT OF SUBSTITUTION

FIGURE 10. HIGH COMPETITIVE RIVALRY

FIGURE 11. GLOBAL PNEUMONIA TESTING MARKET: RESTRAINTS AND DRIVERS

FIGURE 12. PNEUMONIA TESTING MARKET, SEGMENTATION BY METHOD

FIGURE 13. PNEUMONIA TESTING MARKET, SEGMENTATION BY TECHNOLOGY

FIGURE 14. PNEUMONIA TESTING MARKET, SEGMENTATION BY TYPE

FIGURE 15. PNEUMONIA TESTING MARKET, SEGMENTATION BY END USER

FIGURE 16. ABBOTT: NET SALES, 2014-2016 ($MILLION)

FIGURE 17. ABBOTT: REVENUE SHARE BY SEGMENT, 2016 (%)

FIGURE 18. ABBOTT: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

FIGURE 19. BD: NET SALES, 2014-2016 ($MILLION)

FIGURE 20. BD: REVENUE SHARE BY SEGMENT, 2016 (%)

FIGURE 21. BD: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

FIGURE 22. BIOMERIEUX S.A.: NET SALES, 2014-2016 ($MILLION)

FIGURE 23. BIOMERIEUX S.A.: REVENUE SHARE BY APPLICATION, 2016 (%)

FIGURE 24. BIOMERIEUX S.A.: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

FIGURE 25. BIO-RAD: NET SALES, 2014-2016 ($MILLION)

FIGURE 26. BIO-RAD: REVENUE SHARE BY SEGMENT, 2016 (%)

FIGURE 27. BIORAD: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

FIGURE 28. ROCHE: NET SALES, 2014-2016 ($MILLION)

FIGURE 29. ROCHE: REVENUE SHARE BY SEGMENT, 2016 (%)

FIGURE 30. ROCHE: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

FIGURE 31. HOLOGIC: NET SALES, 2014-2016 ($MILLION)

FIGURE 32. HOLOGIC: REVENUE SHARE BY SEGMENT, 2016 (%)

FIGURE 33. HOLOGIC: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

FIGURE 34. MERIDIAN: NET SALES, 2015-2017 ($MILLION)

FIGURE 35. QUEST DIAGNOSTICS: NET SALES, 2014-2016 ($MILLION)

FIGURE 36. QUEST DIAGNOSTICS: REVENUE SHARE BY SEGMENT, 2016 (%)

FIGURE 37. QUIDEL CORPORATION: NET SALES, 2014-2016 ($MILLION)

FIGURE 38. QUIDEL CORPORATION: REVENUE SHARE BY PRODUCT CATEGORY, 2016 (%)

FIGURE 39. QUIDEL CORPORATION: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

FIGURE 40. THERMO FISHER: NET SALES, 2014-2016 ($MILLION)

FIGURE 41. THERMO FISHER: REVENUE SHARE BY SEGMENT, 2016 (%)

FIGURE 42. THERMO FISHER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

Additional Details

Publisher

Allied Market Research

Publisher Information

Reference

152931 | LI 173776

Number of Pages

243

Report Format

PDF

Allied Market Research Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Pneumonia Partnering 2010-2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Nov 2016 by Current Partnering USD $1,495 More Info
Global Pneumonia Partnering 2010-2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Pneumocystis carinii Pneumonia Global Clinical Trials Review, H2, 2016
Pneumocystis carinii Pneumonia Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical t...
30 Sep 2016 by Global Data USD $2,500 More Info
Respiratory Diseases: Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV, Tuberculosis--Supplier Shares, Competitive Strategies, Country Volume and Sales Segment Forecasts, Technology Trends, Instrumentation Review
About this ReportThis new 366-page report from VPG Market Research presents detailed analysis of the...
28 Jun 2016 by Venture Planning Group (VPG) USD $9,850 More Info
France Respiratory Disease Market: Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV, Tuberculosis--Supplier Shares, Competitive Strategies, Country Volume and Sales Segment Forecasts, Technology Trends, Instrumentation Review
About This ReportThis new 282-page report from VPG Market Research presents detailed analysis of the...
28 Jun 2016 by Venture Planning Group (VPG) USD $1,950 More Info
Germany Respiratory Disease Market: Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV, Tuberculosis--Supplier Shares, Competitive Strategies, Country Volume and Sales Segment Forecasts, Technology Trends, Instrumentation Review
About This ReportThis new 283-page report from VPG Market Research presents detailed analysis of the...
28 Jun 2016 by Venture Planning Group (VPG) USD $1,950 More Info
Italy Respiratory Disease Market: Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV, Tuberculosis--Supplier Shares, Competitive Strategies, Country Volume and Sales Segment Forecasts, Technolog Trends, Instrumentation Review
About This ReportThis new 281-page report from VPG Market Research presents detailed analysis of the...
28 Jun 2016 by Venture Planning Group (VPG) USD $1,950 More Info
Japan Respiratory Disease Market: Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV, Tuberculosis--Supplier Shares, Competitive Strategies, Country Volume and Sales Segment Forecasts, Technology Trends, Instrumentation Review
About This ReportThis new 282-page report from VPG Market Research presents detailed analysis of the...
28 Jun 2016 by Venture Planning Group (VPG) USD $2,400 More Info
Pneumonia: US, Europe, Japan--Market Analysis, Competitive Intelligence, Technology Trends, Opportunities for Suppliers
The report presents a detailed analysis of the Pneumonia diagnostics market in the US, Europe (Franc...
24 Jun 2016 by Venture Planning Group (VPG) USD $4,350 More Info
Global Pneumonia Vaccine Market Outlook 2020
According to a new research, introduction of the 10-valent pneumococcal conjugate vaccine, PCV10, de...
01 Jun 2015 by RNCOS USD $1,500 More Info

This report is published by Allied Market Research

Download Free Report Summary PDF

Pneumonia Testing Market by Method (Immunodiagnostics, Molecular Diagnostics, and Point of Care Testing), Technology (Enzyme Linked Immunosorbent Assay, Immunofluorescence, Western Blot, Polymerase Chain Reaction, Immunohistochemistry, and Others), Type (Analyzers and Consumables), and End User (Hospitals, Diagnostic Laboratories, Homecare, and Others) - Global Opportunity Analysis and Industry Fo | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...